Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 9/20 | 0.59 |
| ▸ | LGALS9 | O00182 | 8/20 | 0.59 |
| ▸ | LGALS1 | P09382 | 8/20 | 0.59 |
| ▸ | LGALS7; LGALS7B | P47929 | 6/20 | 0.59 |
| ▸ | LGALS8 | O00214 | 6/20 | 0.47 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
| ▸ | TACR2 | P21452 | 1/20 | 0.41 |
| ▸ | LGALS2 | P05162 | 2/20 | 0.39 |
| ▸ | LGALS4 | P56470 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SELP | P16109 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24107976 | 0.92 | LGALS9 (0.56) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL3659771 | 0.92 | LGALS9 (0.53) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL17309342 | 0.86 | LGALS3 (0.57) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL19090197 | 0.86 | LGALS3 (0.80) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL17309354 | 0.86 | LGALS3 (0.80) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL22500214 | 0.85 | LGALS3 (0.49) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL19674473 | 0.83 | LGALS3 (0.58) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL19674440 | 0.83 | LGALS3 (0.58) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL21851777 | 0.83 | SLC6A2 (0.53) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL24086075 | 0.83 | SLC6A2 (0.53) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10806746-B2 | Di- and tri-cationic glycosylated antitumor ether lipids, L-gucosylated gaels and rhamnose-linked gaels as cytotoxic agents against epithelial cancer cells and cancer stem cells | THE UNIV OF MANITOBA (CA) | 2020-10-20 | — | — | US | disclosed |
| US-20170189438-A1 | DI- and Tri-Cationic Glycosylated Antitumor Ether Lipids, L-Gucosylated Gaels and Rhamnose-Linked Gaels as Cytotoxic Agents Against Epithelial Cancer Cells and Cancer Stem Cells | THE UNIV OF MANITOBA (CA) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189438-A1 | DI- and Tri-Cationic Glycosylated Antitumor Ether Lipids, L-Gucosylated Gaels and Rhamnose-Linked Gaels as Cytotoxic Agents Against Epithelial Cancer Cells and Cancer Stem Cells | UGCG, PNLIP, B3GAT3 | LGALS3 31/4885LGALS9 176/4885LGALS1 59/4885 |
| US-10806746-B2 | Di- and tri-cationic glycosylated antitumor ether lipids, L-gucosylated gaels and rhamnose-linked gaels as cytotoxic agents against epithelial cancer cells and cancer stem cells | PNLIP, UGCG, LIPC | LGALS3 30/4885LGALS9 152/4885LGALS1 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.